CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended			6 Months Ended			79 Months Ended
	Jun. 30, 2012	Jun. 30, 2011		Jun. 30, 2012	Jun. 30, 2011		Jun. 30, 2012
Costs and Expenses:
Research and development	$ 7,626,268	$ 2,354,450		$ 12,964,408	$ 3,832,576		$ 41,377,562
Purchased in-process research and development							28,156,502
General and administrative	1,918,488	1,524,402		3,649,616	3,422,028		23,294,258
Loss from Operations	(9,544,756)	(3,878,852)		(16,614,024)	(7,254,604)		(92,828,322)
Interest and investment income	48,116	20,003		86,794	44,067		364,980
Interest expense					(11,877)		(11,877)
Other income	255,539			255,539			1,112,516
Change in fair value of derivative instruments-warrants	(1,317,347)	(697,660)		(1,309,401)	(1,036,375)		4,244,414
Total Other Income/(Expense)	(1,013,692)	(677,657)		(967,068)	(1,004,185)		5,710,033
Loss from Continuing Operations	(10,558,448)	(4,556,509)		(17,581,092)	(8,258,789)		(87,118,289)
Loss from discontinued operations							(71,821)
Net Loss	$ (10,558,448)	$ (4,556,509)		$ (17,581,092)	$ (8,258,789)		$ (87,190,110)
Weighted Average Common Shares Outstanding Basic and Diluted (in shares)	60,416,068	46,642,901	[1]	57,357,081	46,406,472	[1]
Net Loss per Common Share, Basic and Diluted (in dollars per share)	$ (0.17)	$ (0.10)	[1]	$ (0.31)	$ (0.18)	[1]

[1] Restated for 1:2 reverse stock split effective November 30, 2011.